(Q44893510)

7 December 2017

title

Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes (English)

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

28 December 2023

0 references

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

28 December 2023

1

Carla J Greenbaum

1 reference

7 December 2017

author name string

Immunology of Diabetes Society

3

1 reference

7 December 2017

Leonard C. Harrison

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12716733

28 December 2023

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

7 December 2017

https://diabetesjournals.org/diabetes/article-pdf/52/5/1059/654943/db0503001059.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12716733

https://journals.org/diabetes/diabetes/article-pdf/52/5/1059/654943/db0503001059.pdf

28 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

https://diabetesjournals.org/diabetes/article-pdf/52/5/1059/654943/db0503001059.pdf

28 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

28 December 2023

1 reference

7 December 2017

volume

52

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

1059-1065

1 reference

The NOD mouse model of type 1 diabetes: as good as it gets?

7 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Serum exchange and use of dilutions have improved precision of measurement of islet cell antibodies.

28 December 2023

3

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Immunology and Diabetes Workshop: report on the Third International (Stage 3) Workshop on the Standardisation of Cytoplasmic Islet Cell Antibodies. Held in New York, New York, October 1987

28 December 2023

4

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

The second International Workshop on the Standardisation of Insulin Autoantibody (IAA) measurement. Held in New York, 27-30 October 1987.

28 December 2023

5

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays.

28 December 2023

6

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of

28 December 2023

9

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Fifth International Serum Exchange Workshop for Insulin Autoantibody (IAA) Standardization. The Immunology and Diabetes Workshops and participating laboratories

28 December 2023

10

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study

28 December 2023

12

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop

28 December 2023

13

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Comparison of two commonly used standard IVGTTs

28 December 2023

14

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Standardization of IVGTT to predict IDDM

28 December 2023

16

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. The ICARUS Group. Islet Cell Antibody Register User's Study

28 December 2023

17

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Reproducibility of the First-Phase Insulin Response to Intravenous Glucose Is Not Improved by Retrograde Cannulation and Arterialization or the Use of a Lower Glucose Dose

28 December 2023

18

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus

28 December 2023

20

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes.

28 December 2023

22

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients

28 December 2023

23

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus

28 December 2023

24

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients

28 December 2023

25

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus

28 December 2023

26

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus.

28 December 2023

27

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Prednisone administration in recent onset type I diabetes

28 December 2023

28

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group

28 December 2023

29

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Effects of a short prednisone regime at clinical onset of type 1 diabetes.

28 December 2023

30

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).

28 December 2023

33

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Antibody response to islet antigens in anti-CD4/prednisolone immune intervention of type 1 diabetes

28 December 2023

35

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients

28 December 2023

36

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.

28 December 2023

37

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial.

28 December 2023

38

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM.

28 December 2023

39

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study

28 December 2023

40

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus

28 December 2023

41

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

28 December 2023

42

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

28 December 2023

43

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes

28 December 2023

44

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Glucose tolerance behaviour before the onset of type I (insulin-dependent) diabetes in young people as a predictor of the further course of the disease: a retrospective analysis of 33 cases

28 December 2023

45

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria

28 December 2023

46

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus

28 December 2023

47

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

HLA antigens and age at diagnosis of insulin-dependent diabetes mellitus

28 December 2023

48

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease.

28 December 2023

49

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes

28 December 2023

50

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Residual B-cell function in type 1 (insulin-dependent) diabetes mellitus: its relation to clinical and metabolic features.

28 December 2023

51

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children

28 December 2023

52

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group

28 December 2023

53

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Insulin autoantibodies are associated with islet cell antibodies; their relation to insulin antibodies and B-cell function in diabetic children.

28 December 2023

55

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes.

28 December 2023

57

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Factors predicting course of beta-cell function in IDDM

28 December 2023

59

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Determinants of clinical remission in recent-onset IDDM.

28 December 2023

60

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Relationship between GAD antibody and residual beta-cell function in children after overt onset of IDDM

28 December 2023

61

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus

28 December 2023

62

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Prognostic factors for the course of beta cell function in autoimmune diabetes

28 December 2023

64

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group

28 December 2023

65

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

A proposal of three distinct subtypes of type 1 diabetes mellitus based on clinical and pathological evidence

28 December 2023

66

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Meal-stimulated C-peptide and insulin antibodies in type I diabetic subjects and their nondiabetic siblings characterized by HLA-DR antigens

28 December 2023

67

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies

28 December 2023

69

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage

28 December 2023

70

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency

28 December 2023

71

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA).

28 December 2023

73

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Diabetic autoimmune markers in children and adolescents with type 2 diabetes

28 December 2023

74

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

beta-cell function in children with diabetes

28 December 2023

75

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

28 December 2023

78

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

28 December 2023

83

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

28 December 2023

85

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group.

28 December 2023

86

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

C-Peptide reserve in insulin-dependent diabetes. Comparative responses to glucose, glucagon and tolbutamide

28 December 2023

87

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

C-peptide response to arginine stimulation in diabetic children

28 December 2023

88

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Residual C-peptide production in type I diabetes mellitus. A comparison of different methods of assessment and influence on glucose control.

28 December 2023

91

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group

28 December 2023

93

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients.

28 December 2023

94

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Urinary excretion rate of C-peptide in fed and fasted obese humans.

28 December 2023

95

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Residual beta-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve

28 December 2023

96

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Reproducibility of the glucagon test.

28 December 2023

97

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Methodological aspects on C-peptide measurements.

28 December 2023

98

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients.

28 December 2023

99

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus

28 December 2023

100

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Carbimazole and the Autoimmune Response in Graves' Disease

28 December 2023

102

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy

28 December 2023

103

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes

28 December 2023

104

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Islet-reactive T cells are a marker of preclinical insulin-dependent diabetes

28 December 2023

106

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Neural network-based prediction of candidate T-cell epitopes.

28 December 2023

108

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays

28 December 2023

109

1 reference

https://api.crossref.org/works/10.2337/DIABETES.52.5.1059

28 December 2023

Identifiers

1 reference

7 December 2017

1 reference